Find out more about each of our sponsors by reading their summary biographies or visiting their websites. To learn about our bespoke partnership opportunities and how you can get your brand in front of our dedicated neoantigen audience, view our why partner page, download the 2023 event guide or get in touch with us.
Personalis, Inc. is a leader inadvanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample.
NEC OncoImmunity is a bioinformatics company offering proprietary machinelearning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in clinically actionable timeframe.
Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personlised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.
Provepharm Life Solutions is a pharmaceutical and a CDMO company commercializing immunopeptide services since 2003. Pionner in the chemical synthesis of + 100 mer long peptide we delivered our first clinical batch of a 96-mer peptide in 2006. Specialized in microgram therapies we have developed a one-stopshop offer for the delivery of ready to use peptide-based drug products including conjugates. For personalized peptide vaccine programs we designed a GMP manufacturing process to deliver up to 40 neoantigens every 6 weeks.
Biosynth’s vision is to consolidate the highly fragmented and complex supply chain by executing an aggressive buy and build strategy. Biosynth increases productivity of the pharmaceutical and diagnostics industries by improving availability and reducing time-to-market of new therapies and diagnostics assays. Biosynth is viewed as a strategic partner to many of the leading companies in the market.
We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world working in targeted therapies to provide accurate, in-depth and real-time drugs and trials data in the rapidly evolving landscape of drug development.
BCN Peptides is completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical applications.
- Synthesis of API Peptides. We manufacture multikilo batches using SPPS technology. Excellent GMP compliance: PMDA, US-FDA and EDQM Approved. BCN Peptides Manufactures from milligrams up to Commercial Quantities.
- Production of Neoantigen Peptides for Personalized Medicine. Our Peptide-based Personalised Medicine Laboratory (PPM Lab) has been designed and equipped with state-of-the-art technology to meet the unique requirements of neoantigens production. The implementation of automatization systems, together with a fit-for-purpose quality system allows for high-speed production and fully compliant GMP manufacturing with complete traceability of the entire process. The best quality and fast turnaround time.
BioConnection is a contract manufacturer for the GMP production of sterile drug products (in vials or syringes) for clinical trial programs and commercial purposes. Our state-of-the-art GMP manufacturing facility is EMA and US-FDA certified, we have more than 14 years of experience and a global customer base. BioConnection offers complete drug product service packages including: filling and freeze drying, technology transfer, scale-up, process validation, analytical support, stability studies, label & pack (incl. serialization) and final GMP release.
We have 4 different aseptic production lines in 1 facility in which we can handle batch sizes ranging from a few hundred vials for personalized medicine purposes up to 150,000 vials (44,300 vials freeze-dried) per batch for commercial purposes